186 related articles for article (PubMed ID: 1373767)
1. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
6. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
8. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Stokkel MP; Han SH; Blijham GH; van Rijk PP
J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
[TBL] [Abstract][Full Text] [Related]
10. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Klutmann S; Bohuslavizki KH
MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
[TBL] [Abstract][Full Text] [Related]
11. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
12. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
[TBL] [Abstract][Full Text] [Related]
13. 186Re-etidronate in breast cancer patients with metastatic bone pain.
Han SH; Zonneberg BA; de Klerk JM; Quirijnen JM; van het Schip AD; van Dijk A; Blijham GH; van Rijk PP
J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
[TBL] [Abstract][Full Text] [Related]
14. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
Quirijnen JM; Han SH; Zonnenberg BA; de Klerk JM; van het Schip AD; van Dijk A; ten Kroode HF; Blijham GH; van Rijk PP
J Nucl Med; 1996 Sep; 37(9):1511-5. PubMed ID: 8790203
[TBL] [Abstract][Full Text] [Related]
16. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
17. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model.
Geldof AA; van den Tillaar PL; Newling DW; Teule GJ
Urology; 1997 May; 49(5):795-801. PubMed ID: 9145995
[TBL] [Abstract][Full Text] [Related]
18. Rhenium-188-HEDP in the palliative treatment of bone metastases.
Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG
Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533
[TBL] [Abstract][Full Text] [Related]
19. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
[TBL] [Abstract][Full Text] [Related]
20. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones.
Uehara T; Jin ZL; Ogawa K; Akizawa H; Hashimoto K; Nakayama M; Arano Y
Nucl Med Biol; 2007 Jan; 34(1):79-87. PubMed ID: 17210464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
